mProX™ Human ROS1 Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- Kinase Cell Lines
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
There are currently no Customer reviews or questions for mProX™ Human ROS1 Stable Cell Line (S01YF-1023-PY90). Click the button above to contact us or submit your feedback about this product.
Skyler Brown (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Skyler Williams (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Published Data
Fig.1 The inhibition of gastric cancer cell migration is achieved through the downregulation of ROS1.
The invasion abilities of the cells in the three groups were evaluated through a Transwell assay, with the results presented as mean±SD. A statistically significant difference (P<0.01) was observed when comparing each group to the shCtr group.
Ref: Qiao, Jingjing, et al. "Knockdown of ROS proto-oncogene 1 inhibits migration and invasion in gastric cancer cells by targeting the PI3K/Akt signaling pathway." OncoTargets and therapy 12 (2019): 8569.
Pubmed: 31802893
DOI: 10.2147/OTT.S213421
Research Highlights
Minna, Emanuela. et al. "Genomic and transcriptomic analyses of thyroid cancers identify DICER1 somatic mutations in adult follicular-patterned RAS-like tumors." Frontiers in endocrinology, 2023.
Recent genetic and molecular studies have identified Papillary thyroid carcinoma (PTC) as the predominant type of thyroid cancer (TC). Various investigations examined the genomic and transcriptomic profiles of TCs arising from follicular cells, revealing the presence of gain-of-function mutations in BRAF as a common driver of PTC. These findings indicate the importance of understanding the molecular landscape of PTC in the development of effective diagnostic and treatment strategies for this prevalent cancer type.
Minna, Emanuela. et al. "Genomic and transcriptomic analyses of thyroid cancers identify DICER1 somatic mutations in adult follicular-patterned RAS-like tumors." Frontiers in endocrinology, 2023.
Pubmed:
37867524
DOI:
10.3389/fendo.2023.1267499
Cui, Yongmei. et al. "Dishevelled Segment Polarity Protein 3: A Novel Prognosis-related Marker in Pan-driver-gene-negative Lung Adenocarcinoma." Journal of Cancer, 2023.
This article is about a study that identified a novel prognostic marker for lung cancer patients who do not have any known driver gene mutations. The marker is a protein called DVL3, which is overexpressed in tumor tissues compared to normal tissues. The study used tissue microarrays to measure the level of DVL3 in 626 patients from three independent cohorts and found that high DVL3 expression was associated with shorter overall survival. The study suggests that DVL3 may be a useful biomarker and a potential therapeutic target for this type of lung cancer.
Cui, Yongmei. et al. "Dishevelled Segment Polarity Protein 3: A Novel Prognosis-related Marker in Pan-driver-gene-negative Lung Adenocarcinoma." Journal of Cancer, 2023.
Pubmed:
37859822
DOI:
10.7150/jca.87722
